Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug
development company built on a pathway pharmacology technology platform,
today announced that company management will present at the Oppenheimer
26th Annual Healthcare Conference. The Oppenheimer 26th
Annual Healthcare Conference will be held December 8 - 9, 2015, at the
Westin New York Grand Central Hotel in New York.
-
Jill C. Milne, Ph.D., chief executive officer, will present a
Catabasis corporate and pipeline overview at the Oppenheimer 26th
Annual Healthcare Conference on December 8, 2015, at 8:35am local time
at the Westin New York Grand Central Hotel.
A webcast of the Oppenheimer 26th Annual Healthcare
Conference presentation will be available in the Investors section of
the Company’s website, www.catabasis.com,
and will be archived for 30 days following the presentation.
About CAT-1004
CAT-1004 is an oral small molecule that
inhibits activated NF-kB, a protein that coordinates cellular response
to muscular damage, stress and inflammation and plays an important role
in muscle health. In skeletal muscle, activated NF-kB drives muscle
degeneration and suppresses muscle regeneration. In animal models of
DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and
degeneration and increased muscle regeneration. In Phase 1 clinical
trials, CAT-1004 inhibited activated NF-kB and was well tolerated with
no observed safety concerns. The FDA has granted CAT-1004 orphan drug,
fast track and rare pediatric disease designations for the treatment of
DMD. The European Commission has granted CAT-1004 orphan medicinal
product designation for DMD. Catabasis is currently conducting the
MoveDMD Phase 1 / 2 trial of CAT-1004 in 4-7 year-old boys with DMD.
About CAT-2054
CAT-2054 is an investigational oral drug
initially being developed for the treatment of hypercholesterolemia in
patients for whom existing therapies are insufficient. By modulating the
SREBP pathway, CAT-2054 may inhibit production of important cholesterol
metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase
and NPC1L1. If approved, CAT-2054 may have the potential to be the first
therapy to simultaneously modulate cholesterol synthesis, clearance and
absorption. Catabasis has completed a Phase 1 trial of CAT-2054 in
healthy volunteers, announced positive top-line data and is actively
recruiting patients for the Phase 2a trial of CAT-2054 in patients with
hypercholesterolemia.
About Catabasis
Catabasis Pharmaceuticals is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel therapeutics using its
proprietary Safely Metabolized And Rationally Targeted, or SMART, linker
technology platform. The Company's SMART linker technology platform is
based on the concept of treating diseases by simultaneously modulating
multiple targets in one or more related disease pathways. The Company
engineers bi-functional product candidates that are conjugates of two
molecules, or bioactives, each with known pharmacological activity,
joined by one of its proprietary SMART linkers. The SMART linker
conjugates are designed for enhanced efficacy and improved safety and
tolerability. The Company’s focus is on treatments for rare diseases.
The Company is also developing other product candidates for the
treatment of serious lipid disorders. For more information on the
Company's technology and pipeline of drug candidates, please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151202005288/en/
Copyright Business Wire 2015